Protalix BioTherapeutics (PLX)

• Market cap: $171M
• 1 day: 0%
• 5 days: -3.64%
• 1 month: 1.44%
• 3 months: 2.42%
• 6 months: -10.55%
• Year to date: 21.84%
• 1 year: -28.38%
• 5 years: -40.11%
• 10 years: -74.3%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Employees: 226